Abstract: A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.

Abstract: A method, implemented by a computer, for determining a position of a personal mobility device (PMD) comprises: estimating a position of a PMD based on a first wireless signal; determining whether the PMD is within an intermediate area between a first area and a second area, based on an estimated position of the PMD; determining whether the PMD moves to the second area, by using both the first wireless signal and a second wireless signal; and determining position of the PMD by using any one of the first wireless signal and the second wireless signal based on a movement of the PMD to the second area.

Abstract: The present disclosure relates to a driving mode switching device and a driving mode switching method. Particularly, the driving mode switching device according to the present disclosure comprises: a driving mode switching determination unit for determining to switch a driving mode of a vehicle to either an autonomous driving mode or a manual driving mode on the basis of at least one from among driving information, detection information, and driver detection information; and a driving mode switching unit for controlling a transition section in which the driving mode is switched and/or the ratio of turning control signals in the driving modes on the basis of at least one from among the driving information, the detection information, and the driver detection information when it is determined that the driving mode is to be switched, and switching the driving mode by changing the turning control signal.

Abstract: The present invention relates to oligonucleotides for detection of sepsis-causing bacteria and a detection method using the oligonucleotides, more particularly to a microarry comprising at least one of gram positive bacteria-specific and gram negative bacteria-specific oligonucleotides, sepsis-causing bacteria's genus-specific and species-specific oligonucleotides designed from the ITS target region which is hypervariable base sequence of sepsis-causing bacteria as probes, and a detection method and a diagnosis kit by using the same. According to the present invention, the present invention can provide an antibiotics therapy for accurately removing infectious agent related to sepsis by detecting existence of sepsis-causing bacteria and identifying gram positive- and gram negative-bacteria and genus and species of the bacteria, at once. And, the present invention can prevent a patient from abuse and misuse of antibiotics and decrease time of hospital treatment and medical cost of the patient.

Abstract: The present invention relates to a method so called Bacterial Digitalcode System (BaDis) that identifies microorganism by using bacterial-specific, genus-specific and species-specific oligonucleotides from a variety of samples or specimens for detection and differential diagnosis of microorganism. Particularly, the present invention relates to bacterial-specific, genus-specific and species-specific oligonucleotides designed by the target nucleotide sequences of 23S rDNA or ITS gene, polymerase chain reaction (hereinafter, referred to as “PCR”) kits using the oligonucleotides as a primer, the microarray containing the oligonucleotides as a probe, and methods for detecting microorganism by using the oligonucleotides. Therefore, the present invention can be applied to detect the presence of microorganism and diagnose differentially all microorganism such as pathogenic bacteria of infectious diseases, bacteria inducing food poisoning, bacteria contaminating biomedical products and environmental pollutants.

Abstract: The present invention relates to a method for detecting Mycoplasma and its related strains which are source of contamination of cell lines and biological products and human pathogenic. More particularly, the present invention relates to genus-specific and species-specific oligonucleotides for genotyping of Mycoplasma, Acholeplasm and Ureaplasma strains, microarray comprising the oligonucleotides, and method for detection of species using the microarray. As described above, the present invention provides a rapid and accurate assay method capable of simultaneously detecting many Mycoplasma and its related strains from a single sample using a microarray comprising novel oligonucleotides for detecting Mycoplasma and its related strains which are known as a source of contamination of cell lines and biological products and human pathogenic.

Abstract: Provided are a microarray manufactured using a mixture of target probes for drug-resistant HBV detection, quality control probes for controlling quality in probe hybridization and fabrication of microarrays, and negative control probes for determining the presence and ratio of more than one type, i.e., a wild type and a mutant in a codon, measuring a background of non-specific cross-hybridization, and discriminating homozygotes and heterozygotes, and a method of detecting a drug-resistant HBV, controlling the quality of a microarray, determining the presence and ratio of more than one type, and determining positive and false positive probes at the same time using the microarray. The microarray, which includes the target probes for drug-resistant HBV detection, the QC probes, and the negative control probes, can detect a drug-resistant HBV, control quality in fabrication of microarrays and hybridization, determine the presence and ratio of more than one type, i.e.

Abstract: This invention relates to oligonucleotides sequence of probes or primers for detection or identication of Mycobacterium. In the claimed invention, oligonucleotide sequences of ITS (Internal Transcribing Spacer Region) from M. fortuitium, M. chelonae, M. abscessus, M. vaccae, M. flavescence, M. Asiaticum, M. porcinum, M. acapulcensis and M. diernhoferi have been identified. Using these ITS sequences, PCR primers or hybridization probes for detection or identication of Mycobacterium have been developed and presented as seq ID: 10 to seq ID: 241.

Abstract: The present invention relates to oligonucleotides of probes or primers for detection or identification of Mycobacterium. In the claimed invention, oligonucleotide sequences of ITS (Internal Transcribed Spacer Region) from M. fortuitum, M. chelonae, M. abscessus, M. vaccae, M. flavescens, M. asiaticum, M. porcinum, M. acapulcensis and M. diernhoferi have been identified. Using these ITS sequences, PCR primers or hybridization probes for detection or identification of Mycobacterium have been developed and presented as seq ID: 10 to seq ID: 241.

Abstract: The present invention relates to oligonucleotides of probes or primers for detection or identification of Mycobacterium. In the claimed invention, oligonucleotide sequences of ITS (Internal Transcribed Spacer Region) from M. fortuitum, M. chelonae, M. abscessus, M. vaccae, M. flavescens, M. asiaticum, M. porcinum, M. acapulcensis and M. diernhoferi have been identified. Using these ITS sequences, PCR primers or hybridization probes for detection or identification of Mycobacterium have been developed and presented as seq ID: 10 to seq ID: 241.